Pelthos Therapeutics Inc.
$22.65
Market Cap
$86.71M
Shares Outstanding
3.8M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Feb 16, 2024
Round Lot
100
Locale
US
Day Open
$22.44
Day High
$23.14
Day Low
$21.96
Volume
33.7K
VWAP
$22.59
Prev Close
$22.38
Transactions
--
Acc. Volume
--
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Pelthos Therapeutics Inc. (PTHS) closed the 2026-09-18 session at $22.65, up 1.21% versus the previous close (+0.27). The stock opened at $22.44 and traded between $21.96 and $23.14 during that session. Session trading volume was 34K shares. The volume-weighted average price (VWAP) is $22.59.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Pelthos Therapeutics Inc. has a market capitalization of $86.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. PTHS is listed on the XASE exchange. The company employs approximately 92 people. Pelthos Therapeutics Inc. is headquartered in DURHAM, NC. The recorded listing date is 2024-02-16.
On this page you can find market PTHS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.